Major U.S. equities indexes were little changed Monday morning, ahead of retail sector earnings reports and comments from Federal Reserve Chair Jerome Powell due later in the week.

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, jumped 5% through 9:55 a.m. ET Monday on a series of positive announcements for its GLP-1 products.

The Food and Drug Administration approved Novo Nordisk's popular weight-loss drug Wegovy to treat a form of liver disease. Shares climbed roughly 4.5% in Denmark (read more about [weight-loss drugs' s

Novo Nordisk A/S (NYSE:NVO) is one of the best falling stocks to buy now. On August 7, HSBC maintained a “Hold” rating on Novo Nordisk and lifted the price target to 355 Danish Krone (DKK) from DKK340.

It seems to be holding off on price adjustments demanded by President Trump.

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma recover?